Research articles on GLP-1 medicines, peptides, nootropics, laboratory education, and grey-market quality are collected here in one current library. Browse by topic, read the latest publication cards, and expand the research context section when you want the evidence standards and editorial approach behind the summaries. Every article is educational research reference material—not medical advice, a treatment recommendation, or a substitute for a qualified clinician or the original study.
Latest research articles
-
Amycretin: Novo Nordisk’s Overlooked Oral GLP-1/Amylin Contender Moves to Phase 3
Amycretin, Novo Nordisk’s dual GLP-1/amylin agonist, posted real Phase 2 weight-loss numbers in both injectable and oral form and is now advancing to Phase 3 for obesity. Here’s how it compares to retatrutide and CagriSema.
-
Tirzepatide vs. Semaglutide: What the Head-to-Head SURMOUNT-5 Trial Actually Showed
SURMOUNT-5 put tirzepatide and semaglutide in the same trial, head to head. The result: 20.2% vs 13.7% average weight loss. Here’s what that gap actually means.
-
Rybelsus Gets a Cardiovascular Risk Reduction Indication for Type 2 Diabetes
The FDA expanded Rybelsus’s approval in October 2025 to include cardiovascular risk reduction for adults with type 2 diabetes, closing the gap between oral and injectable semaglutide’s proven benefits.
-
CagriSema Explained: Novo Nordisk’s Semaglutide-Plus-Amylin Answer to Tirzepatide
Novo Nordisk filed CagriSema with the FDA in December 2025, backed by REDEFINE trial data showing 22.7% average weight loss. Here’s how the semaglutide-plus-amylin combination actually works.
-
FDA Approves the Wegovy Pill: The First Oral Semaglutide Built for Weight Loss
The FDA approved the Wegovy pill — oral semaglutide 25mg — on December 22, 2025, delivering 16.6% average weight loss in the OASIS 4 trial. Here’s how it differs from Rybelsus and Lilly’s rival Foundayo.
-
GLP-1 Receptor Agonists: What the Research Shows About Mechanism and Metabolic Effects
Research overview of GLP-1 receptor agonists: the GLP-1 mechanism, approved drugs and their clinical trial data (STEP, SELECT, SURMOUNT), and the investigational pipeline.
-
GLP-1 Research and Fertility: What Studies Show for Women
GLP-1 receptor agonists are being studied in female reproductive health contexts — including PCOS, ovarian function, and fertility outcomes. Here is what published research reports.
-
GLP-1 Research and Male Fertility: What Published Studies Report
Emerging research has examined GLP-1 receptor expression in reproductive tissue. This covers what published studies report about GLP-1 signaling and male reproductive biology.
-
Managing Side Effects in Research: What Animal Studies Report About Peptide Tolerability
Understanding the tolerability profiles reported in research studies is important context for evaluating peptide research. This overview covers what animal and early human studies have reported.
-
Muscle, Recovery, and Growth Hormone Research: What Studies Report
Growth hormone secretagogues and anabolic peptides are among the most-studied compounds in the performance research space. Here is what the published evidence actually shows.
Research context, evidence standards, and editorial approach
How to Use These Research Articles
Start with the topic links above to narrow the library, then open an article that matches your question. Compound profiles provide a quick orientation to names, mechanisms, research status, and linked literature, while full research articles explain study design, reported outcomes, and important limitations in more detail. Use publication dates and categories to understand context, and follow source links when you need to check the underlying paper, regulatory notice, or public record.
How We Read the Evidence
A finding in a randomized human trial does not carry the same weight as an observational association, an animal experiment, or an in-vitro result. When reading research articles, check the population, comparison group, sample size, follow-up period, measured endpoint, and whether the result was a primary or exploratory analysis. A plausible mechanism can explain why a compound is being studied, but it cannot establish human safety or efficacy by itself. We also separate approved medicines from investigational compounds and research-use-only materials so readers do not confuse biological interest with regulatory status.
Questions to Ask Before Drawing a Conclusion
- Was the study conducted in humans, animals, cells, or a laboratory model?
- Was there a control or comparison group, and was the study large enough to support the claim?
- Does the reported endpoint measure a meaningful outcome or only a short-term marker?
- Are the results peer reviewed, publicly registered, and reproducible?
- Does the article link to the primary source so the methods and limitations can be checked?
- What remains unknown, especially about long-term safety, product quality, or generalizability?
Editorial Approach and Primary Sources
GLP1Place aims to make technical research easier to follow without turning uncertain findings into promises. Articles identify whether evidence is clinical, observational, preclinical, mechanistic, or regulatory, and they use cautious language when a study cannot establish cause and effect. For primary literature, compare the article summary with PubMed research results and the original publication whenever a claim matters. Sources may change over time, so readers should verify current notices and consult qualified professionals for personal medical decisions.
Keeping Research Current
Research moves quickly, especially in obesity medicine, peptide science, cognitive research, and product-quality oversight. A newer paper may add context without overturning every earlier finding, while an agency alert or later correction can change how a claim should be understood. For that reason, this Blog page is organized as a living research library rather than a static list of conclusions. Check publication dates, read the most recent update when available, and treat headlines as a guide to the evidence—not as proof that a compound works, is safe, or is appropriate for a particular person. This page also connects related topics so readers can compare clinical research with preclinical studies and regulatory reporting in the same subject area.
Educational and research reference only: the information on GLP1Place is not medical advice, a diagnosis, or a treatment recommendation.
Use category archives to compare related reports and compound profiles; the date, category, and source context help explain how each item fits the broader research record. When a claim matters, start with the linked primary source and the relevant regulatory notice.